ALFA Filings
Every announcement, straight from the exchange
Every Strides Pharma Science results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
Strides reported strong FY26 performance with EBITDA reaching ₹9,253 million. The Board recommended a dividend of ₹5 per share, reflecting robust growth in Ex-US markets.